<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549523</url>
  </required_header>
  <id_info>
    <org_study_id>U19AT003264-01</org_study_id>
    <secondary_id>U19AT003264-01</secondary_id>
    <secondary_id>TICIPS002_RP01 (E295/05)</secondary_id>
    <nct_id>NCT00549523</nct_id>
  </id_info>
  <brief_title>A Controlled Study of the Safety and Efficacy of Lessertia Frutescens in HIV-infected South African Adults</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of Lessertia Frutescens (L.)Goldblatt and J.C. Manning (Syn. Sutherlandia Frutescens (L.)R. Br.)in HIV-infected South African Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a 2-stage, double-blind, randomized, placebo-controlled study in which fifty-six
      HIV-positive subjects will be randomized into the first stage. Interim analysis to determine
      continuation to stage 2 will be performed to determine continuation after 8 subjects per arm
      have completed a 24-week dosing regimen.

      Primary objectives are to determine the safety of Lessertia frutescens when used by HIV-1
      infected adults with early disease, and to document the impact of Lessertia frutescens on
      markers of HIV disease progression. Secondary objective is to determine the effect of
      Lessertia frutescens on quality of life in HIV-infected adults and length of infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a 2-stage, double-blind, randomized, placebo-controlled study following a
      two-stage, statistical selection theory design. Fifty-six HIV positive subjects will be
      randomized onto Stage 1 that will comprise a 4-arm parallel group (one placebo and 3
      treatment groups) trial. One or possibly two interim analyses will be performed to determine
      continuation to Stage 2. A blinded interim analysis to determine the superior active
      treatment arm of Stage 1 will be continued to Stage 2 after 8 subjects per arm have completed
      the 24-week dosing regimen and the interim analysis. The study will be terminated if the
      interim analysis identifies either significant safety issues, or demonstrable
      non-significance. Following a significant outcome in the blinded interim analysis, the
      selected active and placebo control arms will continue blinded until total n=48 participants
      per arm for the placebo and selected treatment group have completed 24 weeks per arm.
      Respective groups will receive capsules containing L. frutescens in dosages of 0 (placebo
      material), 400mg bid, 800 mg bid or 1200 mg bid in the first stage. Progression to stage 2
      will utilize a two arm design in which 34 subjects will receive either 0 mg L. frutescens
      (placebo) or the active dosage of L. frutescens bid for 24 weeks.

      Primary objectives are to determine the safety of Lessertia frutescens when used by HIV-1
      infected adults with early disease, and to document the impact of Lessertia frutescens on
      markers of HIV disease progression. Secondary objective is to determine the effect of
      Lessertia frutescens on quality of life in HIV-infected adults and length of infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary: determine safety of L. frutescens when used by HIV-1 infected adults with early disease, and to document disease progression.</measure>
    <time_frame>24 week treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary: Determine the effect of L. frutescens on quality of life in HIV-1 infected adults, and length of infection.</measure>
    <time_frame>24 week treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (capsule filled with inert materials)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg bid Lessertia Frutescens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg bid Lessertia Frutescens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 bid Lessertia Frutescens</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules containing 0 mg bid (placebo)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose</intervention_name>
    <description>Capsules containing 400 mg bid of L. frutescens.</description>
    <arm_group_label>Low Dose</arm_group_label>
    <other_name>Lessertia Frutescens</other_name>
    <other_name>Sutherlandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mid Dose</intervention_name>
    <description>Capsules containing 800 mg bid of L. frutescens.</description>
    <arm_group_label>Mid Dose</arm_group_label>
    <other_name>Lessertia Frutescens</other_name>
    <other_name>Sutherlandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose</intervention_name>
    <description>Capsules containing 1200 mg bid of L. frutescens.</description>
    <arm_group_label>High Dose</arm_group_label>
    <other_name>Lessertia Frutescens</other_name>
    <other_name>Sutherlandia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21 - 65 years

          -  HIV-1 infection documented by two different rapid tests for HIV-1 antibodies

          -  CD4 count &gt;350 cells/ul

          -  Viral load&lt; 20,000 copies/mL

          -  Normal hematological function

          -  Absence of clinically significant renal disease

          -  Normal liver function

          -  Random glucose &lt; 11.1 mmol/L

          -  Normal electrocardiogram

          -  Regular attendance at the Wellness Clinic for at least 4 visits

          -  Cognitive capacity sufficient to provide informed consent

        Exclusion Criteria:

          -  Any AIDS-defining diagnosis

          -  Weight loss &gt; 5% of body weight within the preceding six months

          -  Other features of undiagnosed tuberculosis (including cough, fatigue, drenching night
             sweats and abnormal chest radiograph)

          -  Any other significant disease (active TB, hypertension, diabetes mellitus and other
             endocrine disorders, peptic ulcer disease, gastrointestinal malabsorption, psychiatric
             illness) either newly diagnosed or controlled by medication.

          -  Use of any allopathic or traditional medicine other than isoniazid for TB prophylaxis.

          -  Prior or current use of antiretroviral therapy

          -  History of allergic conditions or drug allergy/hypersensitivity

          -  Either history or family history of autoimmune disease

          -  Alcohol use of &gt;7 units per week or &gt;3 per session, tobacco use of more than 10
             cigarettes per day or description of recreational drug use within the past 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Folk, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, Edendale Hospital, Pvt Bag X 509</name>
      <address>
        <city>Pietermaritzburg</city>
        <zip>3216</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <reference>
    <citation>Johnson Q, Syce J, Nell H, Rudeen K, Folk WR. A randomized, double-blind, placebo-controlled trial of Lessertia frutescens in healthy adults. PLoS Clin Trials. 2007 Apr 27;2(4):e16.</citation>
    <PMID>17476314</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2007</study_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Alternative Medicine</keyword>
  <keyword>Complementary Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

